Cargando…
Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial
BACKGROUND: Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488323/ https://www.ncbi.nlm.nih.gov/pubmed/22937736 http://dx.doi.org/10.1186/1745-6215-13-156 |
_version_ | 1782248601495273472 |
---|---|
author | Chang, Anne B Grimwood, Keith Robertson, Colin F Wilson, Andrew C van Asperen, Peter P O’Grady, Kerry-Ann F Sloots, Theo P Torzillo, Paul J Bailey, Emily J McCallum, Gabrielle B Masters, Ian B Byrnes, Catherine A Chatfield, Mark D Buntain, Helen M Mackay, Ian M Morris, Peter S |
author_facet | Chang, Anne B Grimwood, Keith Robertson, Colin F Wilson, Andrew C van Asperen, Peter P O’Grady, Kerry-Ann F Sloots, Theo P Torzillo, Paul J Bailey, Emily J McCallum, Gabrielle B Masters, Ian B Byrnes, Catherine A Chatfield, Mark D Buntain, Helen M Mackay, Ian M Morris, Peter S |
author_sort | Chang, Anne B |
collection | PubMed |
description | BACKGROUND: Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis exacerbations, but not all practitioners agree. Inadequately treated exacerbations may risk lung function deterioration. Our study tests the hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of respiratory exacerbations by day 14 in children with bronchiectasis unrelated to cystic fibrosis. METHODS: We are conducting a bronchiectasis exacerbation study (BEST), which is a multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel group trial, in five centres (Brisbane, Perth, Darwin, Melbourne, Auckland). In the component of BEST presented here, 189 children fulfilling inclusion criteria are randomised (allocation-concealed) to receive amoxicillin-clavulanic acid (22.5 mg/kg twice daily) with placebo-azithromycin; azithromycin (5 mg/kg daily) with placebo-amoxicillin-clavulanic acid; or placebo-azithromycin with placebo-amoxicillin-clavulanic acid for 14 days. Clinical data and a paediatric cough-specific quality of life score are obtained at baseline, at the start and resolution of exacerbations, and at day 14. In most children, blood and deep nasal swabs are also collected at the same time points. The primary outcome is the proportion of children whose exacerbations have resolved at day 14. The main secondary outcome is the paediatric cough-specific quality of life score. Other outcomes are time to next exacerbation; requirement for hospitalisation; duration of exacerbation; and spirometry data. Descriptive viral and bacteriological data from nasal samples and blood markers will also be reported. DISCUSSION: Effective, evidence-based management of exacerbations in people with bronchiectasis is clinically important. Yet, there are few randomised controlled trials (RCTs) in the neglected area of non-cystic fibrosis bronchiectasis. Indeed, no published RCTs addressing the treatment of bronchiectasis exacerbations in children exist. Our multicentre, double-blind RCT is designed to determine if azithromycin and amoxicillin-clavulanic acid, compared with placebo, improve symptom resolution on day 14 in children with acute respiratory exacerbations. Our planned assessment of the predictors of antibiotic response, the role of antibiotic-resistant respiratory pathogens, and whether early treatment with antibiotics affects duration and time to the next exacerbation, are also all novel. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Register (ANZCTR) number ACTRN12612000011886. |
format | Online Article Text |
id | pubmed-3488323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34883232012-11-04 Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial Chang, Anne B Grimwood, Keith Robertson, Colin F Wilson, Andrew C van Asperen, Peter P O’Grady, Kerry-Ann F Sloots, Theo P Torzillo, Paul J Bailey, Emily J McCallum, Gabrielle B Masters, Ian B Byrnes, Catherine A Chatfield, Mark D Buntain, Helen M Mackay, Ian M Morris, Peter S Trials Study Protocol BACKGROUND: Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis exacerbations, but not all practitioners agree. Inadequately treated exacerbations may risk lung function deterioration. Our study tests the hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of respiratory exacerbations by day 14 in children with bronchiectasis unrelated to cystic fibrosis. METHODS: We are conducting a bronchiectasis exacerbation study (BEST), which is a multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel group trial, in five centres (Brisbane, Perth, Darwin, Melbourne, Auckland). In the component of BEST presented here, 189 children fulfilling inclusion criteria are randomised (allocation-concealed) to receive amoxicillin-clavulanic acid (22.5 mg/kg twice daily) with placebo-azithromycin; azithromycin (5 mg/kg daily) with placebo-amoxicillin-clavulanic acid; or placebo-azithromycin with placebo-amoxicillin-clavulanic acid for 14 days. Clinical data and a paediatric cough-specific quality of life score are obtained at baseline, at the start and resolution of exacerbations, and at day 14. In most children, blood and deep nasal swabs are also collected at the same time points. The primary outcome is the proportion of children whose exacerbations have resolved at day 14. The main secondary outcome is the paediatric cough-specific quality of life score. Other outcomes are time to next exacerbation; requirement for hospitalisation; duration of exacerbation; and spirometry data. Descriptive viral and bacteriological data from nasal samples and blood markers will also be reported. DISCUSSION: Effective, evidence-based management of exacerbations in people with bronchiectasis is clinically important. Yet, there are few randomised controlled trials (RCTs) in the neglected area of non-cystic fibrosis bronchiectasis. Indeed, no published RCTs addressing the treatment of bronchiectasis exacerbations in children exist. Our multicentre, double-blind RCT is designed to determine if azithromycin and amoxicillin-clavulanic acid, compared with placebo, improve symptom resolution on day 14 in children with acute respiratory exacerbations. Our planned assessment of the predictors of antibiotic response, the role of antibiotic-resistant respiratory pathogens, and whether early treatment with antibiotics affects duration and time to the next exacerbation, are also all novel. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Register (ANZCTR) number ACTRN12612000011886. BioMed Central 2012-08-31 /pmc/articles/PMC3488323/ /pubmed/22937736 http://dx.doi.org/10.1186/1745-6215-13-156 Text en Copyright ©2012 Chang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Chang, Anne B Grimwood, Keith Robertson, Colin F Wilson, Andrew C van Asperen, Peter P O’Grady, Kerry-Ann F Sloots, Theo P Torzillo, Paul J Bailey, Emily J McCallum, Gabrielle B Masters, Ian B Byrnes, Catherine A Chatfield, Mark D Buntain, Helen M Mackay, Ian M Morris, Peter S Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title | Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title_full | Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title_fullStr | Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title_full_unstemmed | Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title_short | Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
title_sort | antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488323/ https://www.ncbi.nlm.nih.gov/pubmed/22937736 http://dx.doi.org/10.1186/1745-6215-13-156 |
work_keys_str_mv | AT changanneb antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT grimwoodkeith antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT robertsoncolinf antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT wilsonandrewc antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT vanasperenpeterp antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT ogradykerryannf antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT slootstheop antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT torzillopaulj antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT baileyemilyj antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT mccallumgabrielleb antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT mastersianb antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT byrnescatherinea antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT chatfieldmarkd antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT buntainhelenm antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT mackayianm antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial AT morrispeters antibioticsforbronchiectasisexacerbationsinchildrenrationaleandstudyprotocolforarandomisedplacebocontrolledtrial |